(Q47993991)

English

A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice

scientific article published in March 2004

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

A mixed Th1/Th2 response elicited by a liposomal formulation of Leishmania vaccine instructs Th1 responses and resistance to Leishmania donovani in susceptible BALB/c mice (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

1 reference

based on heuristic

inferred from title

Leishmania donovani

object named as

Leishmania donovani

1 reference

based on heuristic

inferred from title

author name string

Tuhina Mazumdar

1

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

Khairul Anam

2

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

Nahid Ali

3

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

language of work or name

0 references

publication date

1 March 2004

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

22

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

9-10

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

1162-1171

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

Leishmaniasis: current status of vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Drug resistance in Indian visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

New perspectives on a subclinical form of visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Vaccines for parasitic and bacterial diseases

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Leishmania mexicanaandLeishmania major:Attenuation of Wild‐Type Parasites and Vaccination with the Attenuated Lines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Immune responses to an inactive vaccine against American cutaneous leishmaniasis together with granulocyte-macrophage colony-stimulating factor

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Immunization of mice against Leishmania donovani by subcutaneous injections of dead promastigotes.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Long lasting protection against canine kala-azar using the FML-QuilA saponin vaccine in an endemic area of Brazil (S�o Gon�alo do Amarante, RN)

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Regulation of protective immunity against Leishmania major in mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Absence of gamma interferon and interleukin 2 production during active visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Novel applications of liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Immunological adjuvants: a role for liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Immunogenicity and protectivity of a new liposomal hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Synthetic lipopeptides incorporated in liposomes: in vitro stimulation of the proliferation of murine splenocytes and in vivo induction of an immune response against a peptide antigen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Liposomes: from biophysics to the design of peptide vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Immunoadjuvant action of liposomes: comparison with other adjuvants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Leishmanicidal activity of stearylamine-bearing liposomes in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Isotype profiles of Leishmania donovani-infected BALB/c mice: preferential stimulation of IgG2a/b by liposome-associated promastigote antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Protection of mice against visceral leishmaniasis by immunization with promastigote antigen incorporated in liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Immunization with a recombinant stage-regulated surface protein from Leishmania donovani induces protection against visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

The adjuvant effect of interleukin-12 in a vaccine against Leishmania major.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Endogenous interleukin-12 regulates acquired resistance in experimental visceral leishmaniasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Macrophage microbicidal mechanisms in vivo: reactive nitrogen versus oxygen intermediates in the killing of intracellular visceral Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Vaccination with recombinant Parasite Surface Antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Protective immunity against the protozoan Leishmania chagasi is induced by subclinical cutaneous infection with virulent but not avirulent organisms.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Immunization with A2 protein results in a mixed Th1/Th2 and a humoral response which protects mice against Leishmania donovani infections

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

CD40L-induced IL-12 production is further enhanced by the Th2 cytokines IL-4 and IL-13

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

IL-4 instructs TH1 responses and resistance to Leishmania major in susceptible BALB/c mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Regional differences in the cellular immune response to experimental cutaneous or visceral infection with Leishmania donovani

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

Adoptive transfer of vaccine-induced resistance to Leishmania donovani.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.09.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2003.09.030

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 February 2018

http://europepmc.org/abstract/MED/15003644

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47993991&oldid=2180934766"